RecruitingPhase 1NCT07289477

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy

Sponsor

iRegene Therapeutics Co., Ltd.

Enrollment

9 participants

Start Date

Jan 5, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

Summary

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.

Eligibility

Min Age: 30 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Human Dopaminergic Progenitor Cells for people with multiple system atrophy - parkinsonian subtype (msa-p). The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.